In essence, the inhibition of IL-17A production in hepatic ILC3s was found to be mediated by SCFAs, synthesized in the colon and metabolized by gut bacterial enzymes, such as L. reuteri [121], underscoring the impact of microbiome metabolites on the tumor immune niche. This evidence concerns the gene IL17A and neoplasm.